Evidence map›Paper›PMID 27539605›Full record

ArticleJournal of the American Society of Nephrology : JASN2017

SGLT2 Inhibitors-Sweet Success for Diabetic Kidney Disease?

Ian H de Boer, Steven E Kahn

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics.Transplant international : official journal of the European Society for Organ Transplantation · 2021
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Ian H de BoerDivision of Nephrology and Kidney Research Institute and deboer@u.washington.edu.
Steven E KahnVeteran Affairs Puget Sound Health Care System, Seattle, Washington.

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 1986 to 2026
$41.4M
Randomized trial of vitamin D and omega-3 fatty acids for diabetic kidney diseaseR01DK088762 · NIDDK · UNIVERSITY OF WASHINGTON · PI DE BOER, IAN H · 2010 to 2019
$4.7M
Vitamin D Catabolism in Chronic Kidney DiseaseR01DK099199 · NIDDK · UNIVERSITY OF WASHINGTON · PI DE BOER, IAN H · 2014 to 2018
$3.2M
Pathogenesis and Impact of Islet AmyloidI01BX001060 · VA · VA PUGET SOUND HEALTHCARE SYSTEM · PI Pandora Luke Januszewski · 2011 to 2026
–
BLRD VA I01 BX001060NIDDK NIH HHS P30 DK017047NIDDK NIH HHS R01 DK088762NIDDK NIH HHS R01 DK099199
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CanagliflozinSodium-Glucose Transporter 2 InhibitorsBlood GlucoseDiabetes Mellitus, Type 2Diabetic NephropathiesDisease ProgressionHumansHypoglycemic AgentsSodium-Glucose Transporter 2Blood GlucoseCanagliflozinHypoglycemic AgentsSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 Inhibitorschronic kidney diseaseclinical trialdiabetes mellitusdiabetic nephropathy

Identifiers

PMID27539605
PMCPMC5198295

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.